10x Genomics, Inc. (NASDAQ:TXG) Insider Benjamin J. Hindson Sells 7,485 Shares

10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) insider Benjamin J. Hindson sold 7,485 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $62,125.50. Following the sale, the insider now directly owns 448,374 shares of the company's stock, valued at $3,721,504.20. This trade represents a 1.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

10x Genomics Stock Performance

Shares of 10x Genomics stock traded up $0.15 on Friday, hitting $9.49. 4,649,181 shares of the company's stock were exchanged, compared to its average volume of 2,426,523. The company has a 50-day simple moving average of $8.46 and a 200-day simple moving average of $11.80. The stock has a market capitalization of $1.17 billion, a PE ratio of -6.24 and a beta of 1.94. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The company had revenue of $154.88 million for the quarter, compared to analysts' expectations of $131.91 million. During the same quarter in the previous year, the company earned ($0.50) EPS. 10x Genomics's revenue for the quarter was down 2.3% on a year-over-year basis. On average, analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Signaturefd LLC lifted its stake in shares of 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after buying an additional 1,452 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of 10x Genomics during the 4th quarter valued at $32,000. Blue Trust Inc. lifted its stake in shares of 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after buying an additional 1,299 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of 10x Genomics during the 4th quarter valued at $52,000. Finally, GAMMA Investing LLC lifted its stake in shares of 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after buying an additional 1,614 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of 10x Genomics from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Morgan Stanley dropped their target price on shares of 10x Genomics from $26.00 to $18.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Stephens restated an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a report on Thursday, May 15th. Stifel Nicolaus dropped their target price on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Finally, Citigroup dropped their target price on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, 10x Genomics currently has an average rating of "Hold" and an average target price of $15.81.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.